A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer
- 31 January 2009
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 63 (1) , 88-93
- https://doi.org/10.1016/j.lungcan.2008.04.003
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- P2-274: Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC)Journal of Thoracic Oncology, 2007
- A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast CancerClinical Cancer Research, 2007
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic CancerClinical Cancer Research, 2007
- A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumoursBritish Journal of Cancer, 2006
- Second-line chemotherapy in recurrent small cell lung cancerLung Cancer, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597Journal of Clinical Oncology, 2003
- Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patientsEuropean Journal Of Cancer, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989